

**CLAIMS****WHAT IS CLAIMED IS:**

1. A method for stimulating angiogenesis in a tissue comprising administering to said tissue an angiogenesis stimulating amount of a pharmaceutical composition comprising an adiponectin protein or angiogenic stimulating portion thereof in a pharmaceutically acceptable carrier or a nucleic acid cassette containing a nucleic acid encoding for adiponectin or angiogenic stimulating portion thereof operably linked to promoter.
2. The method of claim 1, wherein the promoter is inducible.
3. The method of claim 1, wherein said tissue has a disease or disorder associated with insufficient angiogenesis.
4. The method of claim 3, wherein the disease or disorder results in abnormal circulation.
5. The method of claim 1, wherein said tissue is myocardial.
6. The method of claim 3, wherein said disorder is a cardiac disorder.
7. The method of claim 1, wherein the adiponectin protein is a trimer.
8. A method for treating a cardiac disorder comprising administering to a patient having said disorder a pharmaceutical composition comprising adiponectin protein or effective portion thereof or a nucleic acid cassette containing a nucleotide sequence encoding adiponectin or effective portion thereof, operably linked to a promoter.
9. The method of claim 8, wherein said cardiac disorder is associated with abnormal circulation.
10. The method of claim 8, wherein said cardiac disorder is selected from the group consisting of myocardial infarction, cardiac hypertrophy, and cardiac myopathy.
11. The method of claim 8, wherein the adiponectin protein is a trimer.
12. The method of claim 8, wherein the promoter is inducible.

13. A kit for stimulating angiogenesis or treating a cardiac disorder in a target mammalian tissue comprising a composition comprising a nucleic acid cassette containing a nucleic acid segment encoding for adiponectin operably linked to a promoter or a pharmaceutical composition of adiponectin protein or effective portion thereof and a pharmaceutically acceptable carrier or excipient.
14. The kit of claim 13, wherein said tissue has a disease or disorder associated with insufficient angiogenesis.
15. The kit of claim 14, wherein the disorder is a cardiac disorder.
16. The kit of claim 13, wherein the cardiac disorder is selected from the group consisting of myocardial infarction, cardiac hypertrophy, and cardiac myopathy.
17. The use of a pharmaceutical composition for stimulating angiogenesis in a tissue or treating a cardiac disorder comprising an adiponectin protein or angiogenic stimulating portion thereof in a pharmaceutically acceptable carrier or a nucleic acid cassette containing a nucleic acid encoding for adiponectin or angiogenic stimulating portion thereof operably linked to promoter.
18. The use of the pharmaceutical composition of claim 17, wherein said tissue has a disease or disorder associated with insufficient angiogenesis.
19. The use of the pharmaceutical composition of claim 18, wherein the disorder is a cardiac disorder.
20. The use of the pharmaceutical composition of claim 17, wherein the cardiac disorder is selected from the group consisting of myocardial infarction, cardiac hypertrophy, and cardiac myopathy.